Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARR: Everolimus for NK-mediated Rejection After Kidney Transplantation
2024-513814-37-00Phase 4Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of everolimus in kidney allograft rejection, sponsored by Hospices Civils de Lyon. Primary endpoint: Relative variation in GFR (CKD-EPI) from D-15 to Month 6. Planned start Sep 2024; status: authorised.
02
Drugs
everolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2024-513814-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513814-37-00.